Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
1. HIMS and Novo Nordisk announced a long-term collaboration for weight loss. 2. Wegovy is now available via HIMS’ platform for $599 monthly. 3. HIMS' GLP-1 weight loss solutions generated over $225 million in revenue. 4. Partnership improves access to ongoing care and nutrition guidance. 5. HIMS stock surged 35.5% to $38.60 during premarket trading.